ClinicalTrials.gg
Active, not recruitingNCT05429736Updated Sep 1, 2026

Activating Spinal Circuits to Improve Walking, Balance, Strength, and Reduce Spasticity

An interventional study of Motor Skill Training (MST) and Transcutaneous Spinal Stimulation (TSS) in Incomplete Spinal Cord Injury and Spasticity, Muscle, sponsored by Shepherd Center, Atlanta GA. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Shepherd Center, Atlanta GA · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 166 studies in Muscle Spasticity with a site in United States — 34 open to participants now, 44 under way, none of them phase 3. Muscle Spasticity · United States.

Planned enrollment
75th of 131
28 · median 30
Started
2022
with 12 others
No phase
60 of 166
18 open now
Primary completion
2026-09
later than 8 of 43 live
Registered
124th of 166
by date
Lead sponsor
4 of 166
Shepherd Center, Atlanta GA

Among the 166 studies in Muscle Spasticity with a site in United States, this one is the 75th largest by planned enrollment of the 131 interventional ones that give a count, is one of 13 that started in 2022, is one of 60 with no phase, reaches primary completion later than 8 of the 43 other live ones, and was the 124th registered.

Muscle Spasticity

626 studies on the registry are indexed under Muscle Spasticity; 131 are open to participants now.

Browse Muscle Spasticity studies →

Open to participants now

34 of the 166 studies in Muscle Spasticity with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Muscle Spasticity studies recruiting now, 29 (33%) set no upper age limit and 47 (53%) stop at 75 or younger; 34 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies in Muscle Spasticity with a site in United States, or all of them as a file.
02

Study summary

For many people with spinal cord injury (SCI), the goal of walking is a high priority. There are many approaches available to restore walking function after SCI; however, these approaches often involve extensive rehabilitation training and access to facilities, qualified staff, and advanced technology that make practicing walking at home difficult. For this reason, developing training approaches that could be easily performed in the home would be of great value. In addition, non-invasive spinal stimulation has the potential to increase the effectiveness of communication between the brain and spinal cord. Combining motor skill training (MST) with transcutaneous spinal stimulation (TSS) may further enhance the restoration of function in persons with SCI. Therefore, the purpose of this study is to determine if moderate-intensity, MST can improve walking-related outcomes among persons with SCI and to determine if the addition of non-invasive TSS will result in greater improvements in function compared to training alone.

Read the detailed description

Individuals with SCI will be asked to participate in this study over a four-week period. During the first 2 weeks (wash-in phase), individuals will participate in 6 aerobic and exercise training sessions as part of either an existing outpatient clinical program or by completing a personalized exercise plan. During the intervention phase (last 2 weeks), participants will be randomized to complete 6 training sessions of: 1) motor skill training combined with TSS (MST+TSS group) or 2) motor skill training combined with shamTSS (MST+shamTSS). All participants will complete 3 testing sessions: baseline testing 1 (prior the wash-in phase), testing 2 (after the completion of the wash-in phase and prior the intervention phase), and testing 3 (after the completion of the intervention phase) to assess their walking ability, balance, strength, and spasticity. During the intervention phase and to monitor within-session changes, participants will also complete a short version of walking function and balance assessments prior to and after each training session.

03

Conditions studied

  • Incomplete Spinal Cord Injury
  • Spasticity, Muscle

Keywords

  • spinal
  • cord
  • incomplete
  • motor
  • skill
  • training
  • transcutaneous
  • stimulation
  • TSS
  • tSCS
  • electrophysiology
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be 18-70 years of age
  • Have a spinal cord injury (neurological level C3-T12) that occurred ≥3 months (sub-acute to chronic) prior to enrollment
  • Have ISNCSCI severity classification C or D
  • Able to stand for at least 5 minutes (with or without the aid of an assistive device)
  • Able to move each leg independently for at least 3 steps (with or without the aid of an assistive device)
  • Able to rise from sit to stand with moderate assistance from one person
  • Use of prescription medication(s) for control of spasticity if the dosage has not changed in the last 2 weeks and you notify the study staff if your medication(s) change during study participation
  • Ability and willingness to consent and authorize use of personal health information
  • Ability to follow multiple instructions and communicate pain or discomfort

Exclusion criteria

Exclusion Criteria:

  • Progressive spinal lesions including degenerative, or progressive vascular disorders of the spine and/or spinal cord
  • Injuries below the neurological spinal level of T12
  • Pregnant, or if you have reason to believe you are or may become pregnant due to unknown risks to the fetus associated with TSS
  • History of cardiovascular irregularities
  • Presence of orthopedic conditions that would adversely affect participation in exercise
  • Implanted stimulators of any type will be excluded due to unknown potential of electrical stimulation effects (e.g., baclofen pump, epidural spinal stimulator, implanted cardiac defibrillator, diaphragmatic pacemaker)
  • Any cuts or sensitivity of the skin near the level of stimulation
  • Active cancer or history of cancer
  • Inability and unwillingness to consent and authorize use of personal health information
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    MST + TSS

    Individuals will participate in 6 training sessions of MST combined with TSS.

    Behavioral: Motor Skill Training (MST) · Device: Transcutaneous Spinal Stimulation (TSS)

  • Sham comparator
    MST + ShamTSS

    Individuals will participate in 6 training sessions of MST while receiving shamTSS.

    Behavioral: Motor Skill Training (MST)

Interventions

  • BehavioralMotor Skill Training (MST)

    During MST participants will perform a series of 6 motor skill exercises designed to challenge balance, lower extremity coordination, agility, and speed. Five of these activities will be performed while standing to promote upright control and one activity will be performed while seated (alternating toe-tapping) to provide opportunity for active recovery. Participants will perform each exercise for one minute each, until 4 cycles of the circuit have been completed (approximately 45 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). During MST, participants will wear a chest-worn heart rate monitor to ensure that the optimal HRR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.

  • DeviceTranscutaneous Spinal Stimulation (TSS)

    TSS will be delivered using a commercially available neuromuscular electrical stimulator. The active electrode will be positioned directly over the spine at the T11/T12 spinous interspace, and the reference electrode will be positioned over the umbilicus. Stimulation intensity will be gradually increased until paresthesia of the lower legs and feet is achieved or to the highest level each participant can tolerate. Stimulation will be delivered for a total duration of 30 min after paresthesia/ maximum tolerability is reached.

    Also known as: tSCS

06

What researchers measure

Primary outcomes

  1. Change in 10 Meter Walk Test

    Walking speed (as determined by the 10MWT) is the primary outcome measure for assessing walking function. Participants will complete 3 10MWT trials at each testing session, separated by 2 minutes of seated rest. The average walking speed of the 3 walks will be calculated and used in the analyses.

    Time frame: Testing 1(Day 1), Testing 2 (Day 12), Pre/Post Training 1-6 (Days 15, 17, 19, 22, 24, 26), Testing 3 (Day 27)

Secondary outcomes

  1. Change of Spatiotemporal Gait Characteristic (Cadence)

    Gait quality will be assessed from spatiotemporal gait characteristics (cadence \[strides/min\], stride length \[cm\] of the weaker and stronger limbs, and step length symmetry) collected via instrumented walkway as participants completed three, 10MWT trials at each testing session. The average cadence across three walks will be used in the analysis.

    Time frame: Testing 1(Day 1), Testing 2 (Day 12), Pre/Post Training 1-6 (Days 15, 17, 19, 22, 24, 26), Testing 3 (Day 27)

  2. Change of Spatiotemporal Gait Characteristic (Stride Length - Both Lower Extremities)

    Gait quality will be assessed from spatiotemporal gait characteristics (cadence \[strides/min\], stride length \[cm\] of the weaker and stronger limbs, and step length symmetry) collected via instrumented walkway as participants completed three, 10MWT trials at each testing session. The average stride length across three walks will be used in the analysis.

    Time frame: Testing 1(Day 1), Testing 2 (Day 12), Pre/Post Training 1-6 (Days 15, 17, 19, 22, 24, 26), Testing 3 (Day 27)

  3. Change of Spatiotemporal Gait Characteristic (Step Length Symmetry - Symmetry Index)

    Gait quality will be assessed from spatiotemporal gait characteristics (cadence \[strides/min\], stride length \[cm\] of the weaker and stronger limbs, and step length symmetry) collected via instrumented walkway as participants completed three, 10MWT trials at each testing session. The average step length for each leg across three walks will be used to compute the symmetry index (%).

    Time frame: Testing 1(Day 1), Testing 2 (Day 12), Training 1-6 (Days 15, 17, 19, 22, 24, 26), Testing 3 (Day 27)

  4. Change of Berg Balance Scale

    Balance will be measured using the BBS. The BBS total score will be calculated for each participant at each testing session. The total range of scores for the BBS equals 0-56, with higher scores from baseline indicating greater balance performance and lower scores from baseline indicating worsened balance performance. A subset of the BBS will be assess before and after each training session.

    Time frame: Testing 1 (Day 1), Testing 2 (Day 12), Pre/Post Training 1-6 (Days 15, 17, 19, 22, 24, 26), Testing 3 (Day 27)

  5. Change of Falls Efficacy Scale-International Version (FES-I)

    The FES-I total score will be calculated for each participant at each testing session to measure fear of falling. The total range of scores for the FES-I equals 16-64, with lower scores indicating decreased fear of falling.

    Time frame: Testing 1 (Day 1), Testing 2 (Day 12), Testing 3 (Day 27)

  6. Change of Spinal Cord Assessment Tool for Spastic Reflexes

    The SCATS will be used to assess spasticity. The total range of scores possible for the SCATS is 0-18, with a total score of 0 indicating no lower limb spasticity and higher total scores indicating greater spasticity severity.

    Time frame: Testing 1 (Day 1), Testing 2 (Day 12), Testing 3 (Day 27)

  7. Change of Modified 5-Times Sit-to-Stand

    The modified 5-times sit-to-stand test will be used as a measure of functional lower extremity strength. The average time to complete the test will be calculated at each testing session.

    Time frame: Testing 1 (Day 1), Testing 2 (Day 12), Testing 3 (Day 27)

  8. Change of 2 Minute Walk Test

    Functional walking capacity will be measured based on the 2MWT distance. Total distance walked in 2-minutes will be recorded for each participant at each testing session.

    Time frame: Testing 1(Day 1), Testing 2 (Day 12), Testing 3 (Day 27)

  9. Change of Maximal Isometric Strength

    Knee extensor (quadriceps) and ankle plantar flexors (gastrocnemius and soleus) strength will be measured using an isokinetic dynamometer. Maximum knee extensor force will be analyzed based on the maximum force produced over three attempts.

    Time frame: Testing 1(Day 1), Testing 2 (Day 12), Testing 3 (Day 27)

  10. Change of Torque vs Speed Production

    Torque vs speed production will be using an isokinetic dynamometer. Maximum rate of torque production will be calculated based on the highest rate measured over three attempts.

    Time frame: Testing 1(Day 1), Testing 2 (Day 12), Testing 3 (Day 27)

  11. Change of Modified Spinal Cord Injury Spasticity Evaluation Tool (modified SCI-SET)

    The modified SCI-SET is a subjective measure used to assess the effects of spasticity on daily life in people with SCI. It requires participants to recall their past 7 days when rating the impact of spasticity. The scale uses a range of -2 (very problematic) to +1 (helpful).

    Time frame: Testing 1 (Day 1), Testing 2 (Day 12), Testing 3 (Day 27)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Sep 2026, 54 months after the start.

Of 228 non-industry interventional studies with no phase under Muscle Spasticity, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 37. This study's planned 54 months is above that.

Counting every sponsor, half of 236 studies reached it within 15 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2022
First posted
Jun 23, 2022
StartActual
Mar 1, 2022
Primary completionEst.
Sep 2026
CompletionEst.
May 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05429736
Lead sponsor
Shepherd Center, Atlanta GA
Collaborators
National Institute on Disability, Independent Living, and Rehabilitation Research
Responsible party
Edelle Field-Fote, PT, PhD (Principal Investigator, Shepherd Center, Atlanta GA) — Principal investigator
First posted
Jun 23, 2022
Start date
Mar 1, 2022
Primary completion
Sep 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Edelle Field-Fote, PT, PhD
principal investigator · Shepherd Center, Atlanta GA

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion